OncoHost, a technology company, announced the publication of a study in Clinical Lung Cancer demonstrating the impact of its PROphetNSCLC test on first-line treatment decisions for metastatic non-small cell lung cancer patients.
FDA granted accelerated approival to Emrelis (telisotuzumab vedotin-tllv) for the treatment of adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer with high c-Met protein overexpression who have received a prior systemic therapy.
